Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera)
Latest Information Update: 19 May 2021
At a glance
- Drugs Ponesimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms POINT
- Sponsors Actelion Pharmaceuticals
- 23 Feb 2021 The trial has been completed in Portugal (Global End Date: 26 Mar 2020), according to European Clinical Trials Database record.
- 24 Nov 2020 The trial has been completed in Poland (Global End Date: 26 Mar 2020), according to European Clinical Trials Database record.
- 07 May 2020 The trial has been completed in Bulgaria (Global End Date: 26 Mar 2020), according to European Clinical Trials Database record.